Vimarsana
Biggest News Aggregation in the World

Page 2 - Quotient Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Quotient Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Quotient Sciences Today - Breaking & Trending Today

DR MICHAEL MOSLEY: Mystic Mike's predictions for 2024's BIG medical milestones - Vimarsana News

DR MICHAEL MOSLEY: Mystic Mike's predictions for 2024's BIG medical milestones

DR MICHAEL MOSLEY: It's been a good year for medical advances, from new drugs for Alzheimer's to new uses for artificial intelligence such as reading cancer scans.

UK begins test of hormone-free male contraceptive pill, so pregnancy prevention is not just a 'woman's responsibility' - Vimarsana News

UK begins test of hormone-free male contraceptive pill, so pregnancy prevention is not just a 'woman's responsibility'

The pill, YCT-529, is a hormone-free drug, unlike the female pill, and preclinical studies showed it was “99 per cent effective and 100 per cent reversible with no side effects”.

Source: scmp.com
UK launches first trial of hormone-free male birth control pill. Details inside - Vimarsana News

UK launches first trial of hormone-free male birth control pill. Details inside

UK trials hormone-free male pill, YCT-529, blocking vitamin A for contraception. Promising, reversible, and side-effect-free; trial ends June 2024.

UK Begins Test Of Hormone-Free Male Birth Control Pill, 16 Men Take Part in First Trial - Vimarsana News

UK Begins Test Of Hormone-Free Male Birth Control Pill, 16 Men Take Part in First Trial

Unlike the female pill, YCT-529 is hormone-free and prevents sperm production by blocking access to vitamin A.

Source: ndtv.com
Hormone-Free Male Birth Control Pill Enters Human Trials - Vimarsana News

Hormone-Free Male Birth Control Pill Enters Human Trials

YCT-529, a hormone-free male birth control pill by YourChoice Therapeutics, shows promise in preclinical studies, reducing sperm count without hormonal effects.